Novartis: Significantly above estimates in Q1

NEUTRAL, Fair Value CHF109 (+9%)
News published on April Thursday 23, 2015
Share on

Strong quarter for Novartis in Q1 2015 with revenues more or less in line but margins well above expectations. Margins in Pharmaceuticals and at Sandoz both progressed by 140bp and, in the end, continuing operations advanced 80bp. Novartis sticks to its guidance but looks comfortable with it now and could exceed the core EBIT part of it and report double-digit growth in 2015.

For more information please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities